Modulation of Phagocytosis by RCC Medium, IL-6, and M-CSF
| Conditions . | MFI . | |||||
|---|---|---|---|---|---|---|
| Control . | CLB-CHA CM . | Caki-1 CM . | IL-6 . | M-CSF . | IL-6 + M-CSF . | |
| Control antibodies | 8.1 | 41.8 | 28.3 | 75.8 | 56.2 | 94.3 |
| Anti–(IL-6 + IL-6R) | 8.2 | 20.0 | 9.5 | 9.9 | 24.5 | 28.3 |
| Anti–M-CSF | 7.9 | 10.4 | 9.6 | 36.1 | 10.9 | 59.6 |
| Anti–(IL-6 + IL-6R) + anti–M-CSF | 7.8 | 7.1 | 5.7 | 6.8 | 9.7 | 20.6 |
| Conditions . | MFI . | |||||
|---|---|---|---|---|---|---|
| Control . | CLB-CHA CM . | Caki-1 CM . | IL-6 . | M-CSF . | IL-6 + M-CSF . | |
| Control antibodies | 8.1 | 41.8 | 28.3 | 75.8 | 56.2 | 94.3 |
| Anti–(IL-6 + IL-6R) | 8.2 | 20.0 | 9.5 | 9.9 | 24.5 | 28.3 |
| Anti–M-CSF | 7.9 | 10.4 | 9.6 | 36.1 | 10.9 | 59.6 |
| Anti–(IL-6 + IL-6R) + anti–M-CSF | 7.8 | 7.1 | 5.7 | 6.8 | 9.7 | 20.6 |
CD34+ cells were cultured with GM-CSF + TNFα alone or in presence of 10% RCC CM (CLB-CHA CM and Caki-1 CM), IL-6 (20 ng/mL), M-CSF (20 ng/mL), or IL-6 + M-CSF from day 6 to 12. Neutralizing antibodies (control antibodies, anti–[IL-6 + IL-6R], and anti–M-CSF) were added only or in combination at 10 μg/mL. At day 12, cells were tested for their capacity to phagocyte FITC-conjugated 0.5-μm latex beads for 4 hours at 37°C in complete medium. Ingestion of FITC-labeled particules was analyzed on a FACS can. Results are of one experiment representative of four.